NTLA
Price
$9.50
Change
+$0.08 (+0.85%)
Updated
Jan 17 closing price
Capitalization
967.56M
33 days until earnings call
SONN
Price
$1.54
Change
-$0.00 (-0.00%)
Updated
Jan 17 closing price
Capitalization
4.63M
Ad is loading...

NTLA vs SONN

Header iconNTLA vs SONN Comparison
Open Charts NTLA vs SONNBanner chart's image
Intellia Therapeutics
Price$9.50
Change+$0.08 (+0.85%)
Volume$3.33M
Capitalization967.56M
Sonnet BioTherapeutics Holdings
Price$1.54
Change-$0.00 (-0.00%)
Volume$67.09K
Capitalization4.63M
NTLA vs SONN Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. SONN commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and SONN is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (NTLA: $9.50 vs. SONN: $1.54)
Brand notoriety: NTLA and SONN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 119% vs. SONN: 5%
Market capitalization -- NTLA: $967.56M vs. SONN: $4.63M
NTLA [@Biotechnology] is valued at $967.56M. SONN’s [@Biotechnology] market capitalization is $4.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileSONN’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • SONN’s FA Score: 0 green, 5 red.
According to our system of comparison, both NTLA and SONN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while SONN’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 4 bearish.
  • SONN’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, SONN is a better buy in the short-term than NTLA.

Price Growth

NTLA (@Biotechnology) experienced а -6.86% price change this week, while SONN (@Biotechnology) price change was -2.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -1.89%.

Reported Earning Dates

NTLA is expected to report earnings on May 01, 2025.

SONN is expected to report earnings on Nov 29, 2023.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($968M) has a higher market cap than SONN($4.63M). SONN YTD gains are higher at: 5.479 vs. NTLA (-18.525). SONN has higher annual earnings (EBITDA): -11.77M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. SONN (149K). SONN has less debt than NTLA: SONN (131K) vs NTLA (102M). NTLA has higher revenues than SONN: NTLA (43.1M) vs SONN (18.6K).
NTLASONNNTLA / SONN
Capitalization968M4.63M20,903%
EBITDA-527.52M-11.77M4,483%
Gain YTD-18.5255.479-338%
P/E RatioN/A0.29-
Revenue43.1M18.6K231,720%
Total Cash658M149K441,611%
Total Debt102M131K77,863%
FUNDAMENTALS RATINGS
NTLA vs SONN: Fundamental Ratings
NTLA
SONN
OUTLOOK RATING
1..100
559
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
42
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
9696
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (27) in the Biotechnology industry is in the same range as SONN (42) in the null industry. This means that NTLA’s stock grew similarly to SONN’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SONN (100) in the null industry. This means that NTLA’s stock grew similarly to SONN’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as SONN (100) in the null industry. This means that NTLA’s stock grew similarly to SONN’s over the last 12 months.

NTLA's Price Growth Rating (96) in the Biotechnology industry is in the same range as SONN (96) in the null industry. This means that NTLA’s stock grew similarly to SONN’s over the last 12 months.

SONN's P/E Growth Rating (96) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that SONN’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLASONN
RSI
ODDS (%)
Bullish Trend 5 days ago
86%
Bullish Trend 5 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 5 days ago
79%
Momentum
ODDS (%)
Bearish Trend 5 days ago
81%
Bullish Trend 5 days ago
84%
MACD
ODDS (%)
Bearish Trend 5 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 5 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
90%
Advances
ODDS (%)
Bullish Trend 17 days ago
78%
Bullish Trend 13 days ago
80%
Declines
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
89%
Bearish Trend 5 days ago
83%
Aroon
ODDS (%)
Bearish Trend 5 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if NTLA jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+0.85%
BEAM - NTLA
63%
Loosely correlated
+0.17%
EDIT - NTLA
61%
Loosely correlated
-1.61%
CRSP - NTLA
61%
Loosely correlated
+0.57%
PRME - NTLA
58%
Loosely correlated
+0.70%
ALLO - NTLA
57%
Loosely correlated
-1.09%
More

SONN and

Correlation & Price change

A.I.dvisor tells us that SONN and SNBIF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SONN and SNBIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SONN
1D Price
Change %
SONN100%
N/A
SNBIF - SONN
28%
Poorly correlated
N/A
NTLA - SONN
27%
Poorly correlated
+0.85%
PRME - SONN
27%
Poorly correlated
+0.70%
CHRS - SONN
26%
Poorly correlated
-2.11%
ABCL - SONN
26%
Poorly correlated
+1.02%
More